Stock Repurchase Plan Authorized by Cooper Companies (NASDAQ:COO) Board of Directors

Cooper Companies (NASDAQ:COO) announced that its board has authorized a stock repurchase plan on Wednesday, September 9th, RTT News reports. The company plans to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Cooper Companies from $98.00 to $85.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. UBS Group assumed coverage on Cooper Companies in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $75.00 target price for the company. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research note on Friday, June 5th. Needham & Company LLC cut their price target on Cooper Companies from $101.00 to $86.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Finally, JPMorgan Chase & Co. reduced their price objective on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating for the company in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $81.64.

Cooper Companies Stock Down 6.2%

Shares of Cooper Companies stock traded down $4.21 on Wednesday, hitting $63.48. The company had a trading volume of 9,400,604 shares, compared to its average volume of 1,590,605. Cooper Companies has a 1 year low of $58.89 and a 1 year high of $89.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The stock has a 50 day moving average of $72.42 and a 200-day moving average of $70.02. The stock has a market capitalization of $12.38 billion, a price-to-earnings ratio of 53.80, a P/E/G ratio of 1.77 and a beta of 0.82.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same quarter in the prior year, the company posted $0.49 earnings per share. Cooper Companies’s revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, sell-side analysts forecast that Cooper Companies will post 4.63 earnings per share for the current year.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal Q3 non-GAAP EPS of $1.15, exceeding the $1.11-$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while GAAP EPS was $2.24, helped by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: Cash generation and capital returns were strong: free cash flow increased 66% to $273 million, and the company repurchased $339.1 million of stock during the quarter. The board also expanded its share-repurchase authorization from $2 billion to $3 billion. CooperCompanies Completes Strategic Review
• Neutral Sentiment: CooperSurgical revenue rose 2% on a reported basis and 3% organically, but CooperVision revenue was unchanged year over year. Overall quarterly revenue growth was only about 1% and fell short of the roughly $1.10 billion consensus estimate.
• Negative Sentiment: Management guided fiscal 2026 non-GAAP EPS to $4.51-$4.55, below the $4.63 analyst consensus, with revenue guidance of $4.229-$4.252 billion. Fourth-quarter EPS guidance of $1.05-$1.09 was also well below the approximately $1.20 expected by analysts. The Cooper Companies Q3 Earnings Metrics
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because received offers were not sufficiently attractive. Investors may view this as a missed opportunity to unlock value, particularly amid valuation pressure from a new non-hormonal IUD competitor and fertility-related litigation costs. CooperCompanies Strategic Review and Buyback

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.